Jeegar Patel, Ph.D.

Dr. Jeegar Patel is the Chief Scientific Officer at Evommune. Prior to joining Evommune, Jeegar served as Senior Vice President, Research and Nonclinical Development at Kadmon, where he held positions of increasing responsibility and led the research and development organization with a therapeutic focus in fibrosis, immunology and immuno-oncology. He has directly contributed to multiple IND and NDA filings across therapeutic areas, including the development and approval of REZUROCK® by the FDA in July 2021, which led to Sanofi’s $1.9 billion acquisition of Kadmon in late 2021, where he then led Kadmon’s R&D activity integration into Sanofi. Prior to joining Kadmon in 2014, Jeegar was a nonclinical development project leader at ImClone Systems (acquired by Eli Lilly in 2008) and led nonclinical development activities resulting in the approval of Cyramza® (aVEGFR2 Mab), Portrazza® (aEGFR Mab), and Lartruvo® (aPDGFb Mab). Jeegar began his career as a nonclinical development project toxicologist at Abbott Laboratories and Hoechst Marion Roussel. He received his B.S. in pharmacology and toxicology from the University of the Sciences in Philadelphia and his Ph.D. in pharmacology and physiology from Drexel University College of Medicine.